N1VO34 Stock Price and Chart — BMFBOVESPA:N1VO34

Overview

Financials News Ideas Discussions Technicals Seasonals Bonds

Key facts today

Novo Nordisk is investing $1.09 billion in Brazil to boost production of injectable drugs for obesity and diabetes at a new facility, set to open in 2028.

Novo Nordisk may launch its weight-loss injection Wegovy in India earlier than 2026, aiming to compete with U.S. rival Eli Lilly by selling the product in the coming months.

Novo Nordisk's Wegovy faces potential competition from Indian generics after its patent expires in 2026, but the company expects its brands, Ozempic and Wegovy, to remain competitive.

Analyze the impact Analyze the impact

About NOVO NORDISK B A/S

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.